Welcome to our dedicated page for Kineta news (Ticker: KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.
Kineta Inc. news covered a clinical-stage biotechnology company developing immunotherapies in oncology for cancer immune resistance. Recurring updates centered on KVA12123, a VISTA blocking monoclonal antibody evaluated in the VISTA-101 Phase 1/2 trial for advanced solid tumors, including monotherapy cohorts and combination cohorts with KEYTRUDA (pembrolizumab).
Company announcements also addressed clinical data presentations, trial enrollment changes, the TuHURA exclusivity and right-of-first-offer arrangement for KVA12123, corporate restructuring, strategic-alternatives activity, and Kineta's transition from Nasdaq to OTC Pink trading under KANT before its later merger into Kineta, LLC.
Kineta, Inc. (Nasdaq: KA) announced the appointment of Dr. Myriam Chalabi and Dr. Evan Ya-Wen Yu to its Scientific Advisory Board (SAB) on March 1, 2023. Both doctors bring extensive expertise in oncology and immunotherapy, enhancing Kineta's capability to advance its VISTA blocking immunotherapy, KVA12123. Dr. Chalabi focuses on gastrointestinal cancers, while Dr. Yu specializes in genitourinary malignancies. Their addition aims to guide the clinical development of KVA12123, targeting significant unmet medical needs in advanced solid tumors. Kineta strives to develop next-generation immunotherapies, enhancing its leadership team in the fight against cancer.
Kineta, Inc. has completed a reverse merger with Yumanity Therapeutics, which will allow shares to trade on Nasdaq under the ticker symbol KA starting December 19, 2022. This merger is accompanied by a $7.5 million PIPE financing priced at $11.55 per share, with an additional $22.5 million expected to close by March 31, 2023. These funds, along with $7.8 million retained by Yumanity, will support Kineta’s clinical development of KVA12123, a new immunotherapy targeting cancer. Interim data on KVA12123 is anticipated in late 2023.